(April 2, 2020 / Israel Hayom) The U.S. Food and Drug Administration on Wednesday approved the use of chloroquine phosphate and hydroxychloroquine for emergency treatment of COVID-19 patients, despite a lack of clinical data on their efficacy.
According to financial daily Globes, the FDA is recommending controlled clinical trials to test the drugs’ effectiveness in treating COVID-19, the disease caused by the SARS-CoV-2 virus, but is allowing doctors to give them to patients in cases in which they cannot participate in such a trial.
Israeli pharmaceuticals giant Teva, one of the companies manufacturing hydroxychloroquine, announced last month that it would donate 10 million tablets to U.S. hospitals to treat coronavirus patients. Teva’s hydroxychloroquine has been previously approved for treating malaria, lupus and rheumatoid arthritis patients.
The hydroxychloroquine sulfate market in the United States is dominated by generic manufacturers, and in 2019 it amounted to $230 million. Teva’s market share is 9.2 percent, putting it in fourth place in this market, after Prasco (30.5 percent), Sandoz (28.2 percent) and Zydos Cadila (14 percent), the report said.
Also on Wednesday, Israel’s Magen David Adom national emergency service said it will begin treating coronavirus patients with a new “passive vaccine” created from plasma donated by patients who have recovered from the disease.
Magen David Adom deputy director of blood services professor Eilat Shinar explained that it is believed that those who have recovered from COVID-19 have developed special antivirus proteins or antibodies that can help sick patients fight off the disease.
A version of this article first appeared in Israel Hayom.
Support Jewish Journalism
with 2020 Vision
One of the most intriguing stories of the sudden Coronavirus crisis is the role of the internet. With individuals forced into home quarantine, most are turning further online for information, education and social interaction.
JNS's influence and readership are growing exponentially, and our positioning sets us apart. Most Jewish media are advocating increasingly biased progressive political and social agendas. JNS is providing more and more readers with a welcome alternative and an ideological home.
During this crisis, JNS continues working overtime. We are being relied upon to tell the story of this crisis as it affects Israel and the global Jewish community, and explain the extraordinary political developments taking place in parallel.
Our ability to thrive in 2020 and beyond depends on the generosity of committed readers and supporters. Monthly donations in particular go a long way in helping us sustain our operations. We greatly appreciate any contributions you can make during these challenging times. We thank you for your ongoing support and wish you blessings for good health and peace of mind.